Calendrier des promotions Dianthus Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Paramètres de base
IPO date
2023-09-12
ISIN
US2528281080
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 119.7 | 1 |
| P/BV | 2.12 | 7 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -30.71 | 0 |
| ROE | -32.6 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0146 | 10 |
| Debt/Ratio | 0.004 | 10 |
| Debt/Equity | 0.0611 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 315.67 | 10 |
| Rentabilité Ebitda, % | 32.81 | 5 |
| Rentabilité EPS, % | -90.91 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 17.68 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 18.36 $ | 0 $ | 0 $ | -3.7 % | 0 % | 0 % |
| common.calendar.number_days.30d | 21.75 $ | 17.68 $ | 20.08 $ | -18.71 % | 0 % | 0 % |
| common.calendar.number_days.90d | 21.05 $ | 14.86 $ | 23.38 $ | -16.01 % | 0 % | 0 % |
| common.calendar.number_days.180d | 23.99 $ | 14.86 $ | 27.04 $ | -26.3 % | 0 % | 0 % |
| common.calendar.number_days.1y | 20.7 $ | 14.86 $ | 29.9 $ | -14.59 % | 0 % | 0 % |
| common.calendar.number_days.3y | 0.0606 $ | 0.0225 $ | 31.94 $ | 29074.92 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0.5338 $ | 0.0225 $ | 31.94 $ | 3212.1 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 0.0225 $ | 31.94 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 23.18 $ | 14.86 $ | 27.04 $ | -23.73 % | 0 % | 0 % |
Contenu dans l'ETF
| ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| iShares Morningstar Small-Cap Growth ETF | 0.01576 | 595.05 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.00782 | 391.25 | 0.25 |
| 0,01 | 493,15 | 0,15 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Marino Garcia M.B.A. | President, CEO, Secretary & Director | 1966 (59 années) | |
| Mr. Ryan Savitz | CFO and Chief Business Officer & Treasurer | 1989 (36 années) | |
| Mr. Simrat Randhawa M.B.A., M.D. | Chief Medical Officer | 1970 (55 années) | |
| Mr. Edward G. Carr | Chief Accounting Officer | 1969 (56 années) | |
| Mr. Judson Taylor | Head of Technical Operations | ||
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer | ||
| Ms. Jennifer Davis Ruff | VP and Head of Investor Relations & Corporate Affairs. | ||
| Mr. Adam M. Veness Esq. | Senior VP, General Counsel & Secretary | 1986 (39 années) | |
| Ms. Kristina Maximenko | Chief People Officer | ||
| Ms. Rashieda Gluck | Head of Clinical Development Operations |
Informations sur l'entreprise
Adresse: United States, New York, 7 Times Square - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://dianthustx.com
Site web: https://dianthustx.com
